The Influence of Adjuvant Radiotherapy on Patterns of Failure and Survivals in Uterine Carcinosarcoma

Overview

Journal Radiat Oncol J

Specialty Oncology

Date 2012 Sep 18

PMID 22984675

Citations 7

Authors

Hae Jin Park

Hak Jae Kim

Hong-Gyun Wu

Hans Kim

Sung Whan Ha

Soon-Beom Kang

Yong-Sang Song

Noh-Hyun Park

Jae-Won Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the impact of postoperative radiotherapy (PORT) on patterns of failure and survivals in uterine carcinosarcoma patients treated with radical surgery.

Materials And Methods: Between October 1998 and August 2010, 19 patients with stage I-III uterine carcinosarcoma received curative hysterectomy and bilateral salpingo-oophorectomy with or without PORT at Seoul National University Hospital. Their hospital medical records were retrospectively reviewed. PORT and non-PORT groups included 11 and 8 patients, respectively. They were followed for a mean of 22.7 months (range, 7.8 to 126.6 months).

Results: At 5 years, the overall survival rates were 51.9% for entire, 61.4% for PORT, and 41.7% for non-PORT groups, respectively. There was no statistical difference between PORT and non-PORT groups with regard to overall survival (p = 0.682). Seven out of 19 (36.8%) patients showed treatment failures, which all happened within 12 months. Although the predominant failures were distant metastasis in PORT group and loco-regional recurrence in non-PORT group, there was no statistically significant difference in loco-regional recurrence-free survival (LRRFS) (p = 0.362) or distant metastasis-free survival (DMFS) (p = 0.548). Lymph node metastasis was found to be a significant prognostic factor in predicting poor LRRFS (p = 0.013) and DMFS (p = 0.021), while the International Federation Gynecology and Obstetrics (FIGO) stage (p = 0.043) was associated with LRRFS.

Conclusion: Considering that adjuvant radiotherapy after surgical resection was effective to decrease loco-regional recurrence and most treatment failures were distant metastasis, multimodal therapy including surgery, radiotherapy, and chemotherapy might be an optimal treatment for uterine carcinosarcoma patients.

Citing Articles

Lower Extremity Lymphedema in Gynecologic Cancer Patients: Propensity Score Matching Analysis of External Beam Radiation versus Brachytherapy.

Chang W, Kang H, Wu H, Kim H, Jeon S, Lee M Cancers (Basel). 2019; 11(10).

PMID: 31574979 PMC: 6827029. DOI: 10.3390/cancers11101471.

Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Evaluation of an Interesting Case of Uterine Carcinosarcoma with Isolated Appendicular Skeletal Metastases.

Balasubramanian Harisankar C Indian J Nucl Med. 2018; 33(2):152-153.

PMID: 29643680 PMC: 5883437. DOI: 10.4103/ijnm.IJNM_9_18.

Primary splenic carcinosarcoma with local invasion of chest wall: a rare case.

Sun T, Wang G, Zhang Y J Zhejiang Univ Sci B. 2017; 18(8):717-722.

PMID: 28786246 PMC: 5565519. DOI: 10.1631/jzus.B1700262.

Identification of distinct molecular subtypes of uterine carcinosarcoma.

An Y, Wang H, Jie J, Tang Y, Zhang W, Ji S Oncotarget. 2017; 8(9):15878-15886.

PMID: 28178664 PMC: 5362530. DOI: 10.18632/oncotarget.15032.

Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).

Cha J, Kim Y, Park W, Kim H, Kim J, Kim J J Gynecol Oncol. 2016; 27(6):e58.

PMID: 27550404 PMC: 5078821. DOI: 10.3802/jgo.2016.27.e58.

References

Wolfson A, Brady M, Rocereto T, Mannel R, Lee Y, Futoran R . A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007; 107(2):177-85. PMC: 2752331. DOI: 10.1016/j.ygyno.2007.07.070. View

McCluggage W . Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002; 12(6):687-90. DOI: 10.1136/ijgc-00009577-200211000-00001. View

Reed N, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S . Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008; 44(6):808-18. DOI: 10.1016/j.ejca.2008.01.019. View

Callister M, Ramondetta L, Jhingran A, Burke T, Eifel P . Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004; 58(3):786-96. DOI: 10.1016/S0360-3016(03)01561-X. View

Arrastia C, Fruchter R, Clark M, Maiman M, Remy J, Macasaet M . Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol. 1997; 65(1):158-63. DOI: 10.1006/gyno.1997.4629. View

Pecorelli S, Zigliani L, Odicino F . Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009; 105(2):107-8. DOI: 10.1016/j.ijgo.2009.02.009. View

Wong L, See H, Khoo-Tan H, Low J, Ng W, Low J . Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus. Int J Gynecol Cancer. 2006; 16(3):1364-9. DOI: 10.1111/j.1525-1438.2006.00560.x. View

Makker V, Abu-Rustum N, Alektiar K, Aghajanian C, Zhou Q, Iasonos A . A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol. 2008; 111(2):249-54. PMC: 3952566. DOI: 10.1016/j.ygyno.2008.06.035. View

Vaidya A, Horowitz N, Oliva E, Halpern E, Duska L . Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol. 2006; 103(2):684-7. DOI: 10.1016/j.ygyno.2006.05.009. View

10.

Sampath S, Schultheiss T, Ryu J, Wong J . The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2009; 76(3):728-34. DOI: 10.1016/j.ijrobp.2009.02.077. View

11.

Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M . A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005; 97(1):166-70. DOI: 10.1016/j.ygyno.2004.12.006. View

12.

Sartori E, Bazzurini L, Gadducci A, Landoni F, Lissoni A, Maggino T . Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol. 1997; 67(1):70-5. DOI: 10.1006/gyno.1997.4827. View

13.

Silverberg S, Major F, Blessing J, FETTER B, Askin F, Liao S . Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990; 9(1):1-19. DOI: 10.1097/00004347-199001000-00001. View

14.

Manolitsas T, Wain G, Williams K, Freidlander M, Hacker N . Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. Cancer. 2001; 91(8):1437-43. View

15.

Garcia-Martinez E, Egea Prefasi L, Garcia-Donas J, Escolar-Perez P, Pastor F, Gonzalez-Martin A . Current management of uterine sarcomas. Clin Transl Oncol. 2011; 13(5):307-14. DOI: 10.1007/s12094-011-0659-0. View

16.

Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V . CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13(3):176-81. DOI: 10.1016/S1053-4296(03)00031-6. View

17.

George E, Lillemoe T, Twiggs L, Perrone T . Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol. 1995; 14(1):39-44. DOI: 10.1097/00004347-199501000-00007. View

18.

McCluggage W . Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?. J Clin Pathol. 2002; 55(5):321-5. PMC: 1769650. DOI: 10.1136/jcp.55.5.321. View

19.

Pothuri B, Ramondetta L, Eifel P, Deavers M, Wilton A, Alektiar K . Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol. 2006; 103(3):948-51. DOI: 10.1016/j.ygyno.2006.05.039. View

20.

Yamada S, Burger R, Brewster W, Anton D, Kohler M, Monk B . Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000; 88(12):2782-6. DOI: 10.1002/1097-0142(20000615)88:12<2782::aid-cncr17>3.0.co;2-k. View